• ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation
  • Single and multiple ascending doses planned
  • Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. ("Amoytop"), who maintain rights in Greater China.